Bridge­Bio com­pa­ny sells off rare dis­ease can­di­date to Gal­der­ma part­ner

Is­raeli biotech Sol-Gel Tech­nolo­gies an­nounced Fri­day that it got its hands on a rare dis­ease drug can­di­date from Pelle­Pharm for al­most $75 mil­lion, amid claims that the drug has the po­ten­tial to reach a $300 mil­lion mar­ket.

Ex­ecs said on a con­fer­ence call Fri­day morn­ing that patideg­ib, a hedge­hog sig­nal­ing path­way block­er, is be­ing in­ves­ti­gat­ed to treat Gor­lin syn­drome, a rare ge­net­ic dis­or­der that in­creas­es the risk of de­vel­op­ing cer­tain kinds of can­cer such as basal cell skin can­cer and medul­loblas­toma, a type of brain can­cer. The dis­ease af­fects around one in every 31,000 peo­ple, and an es­ti­mat­ed 70,000 peo­ple world­wide.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER